All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1 -mutated AML unfit for intensive chemotherapy and review of the literature

摘要

Key Clinical Message Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1 -mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.